Priority 9 Sight Loss and Vision PSP Childhood Disorder

UNCERTAINTY: Can better treatments for glaucoma in children be developed? (JLA PSP Priority 9)
Overall ranking 9
JLA question ID 0014c/9
Explanatory note No relevant systematic reviews identified at the time of the PSP
Evidence

None identified

Health Research Classification System category Eye
Extra information provided by this PSP
Original uncertainty examples None provided
Systematic reviews that need updating or extending None identified
Ongoing controlled trials

A study of the safety and efficacy of bimatoprost ophthalmic solution in paediatric patients with glaucoma NCT01426113

Study of travoprost ophthalmic solution, 0.004% compared to timolol (0.5% or 0.25%) in pediatric glaucoma patients NCT01652664

A 3 month, multicenter, double-masked safety and efficacy study of travoprost ophthalmic solution, 0.004% compared to timolol (0.5% or 0.25%) in pediatric glaucoma patients - travoprost 0.004% in pediatric glaucoma patients https://www.clinicaltrialsregister.eu/ctr-search/search? query=eudract_number:2012-001324-34

Submitted by Patients
Outcomes to be measured Management and or change of symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs
PSP information
PSP unique ID 0014c
PSP name Sight Loss and Vision - Childhood Onset Eye Disorders
Total number of uncertainties identified by this PSP. 69  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop April and May 2013